NOTE: This is event is being held virtually. Registration is required. Please visit this Zoom link to register and attend: cancer.ucla.edu/JCCCSeminarSeries.
Presented by
Robert L. Ferris, MD, PhD
Director
UPMC Hillman Cancer Center
Dr. Robert Ferris's research is focused on cellular immune mechanisms of natural killer (NK) cell, dendritic cells (DC) and T lymphocyte activation against head and neck cancer (HNC) tumor antigens. In addition his group pioneered studies demonstrating innate and adaptive immune responses induced by EGFR-specific mAb, cetuximab in cancer patients. His laboratory also investigates the role of immunosuppressive molecules, such as immune checkpoint receptors, including PD-1, CTLA-4, TIM-3, and LAG-3. His laboratory is funded by NCI R01 and SPORE grants. The laboratory is also focused on mechanisms of tumor antigen processing and immunologic evasion used by head and neck cancer cells, themselves. New trials are testing combination immunotherapies, through one-month, "window of opportunity" neoadjuvant clinical trials, providing novel and unique pre- and post-treatment specimens to interrogate the tumor microenvironment (TME) for factors that drive personalized cancer immunotherapy.
Light lunch served
Sponsored by the UCLA Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program